Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C13H14N2O.ClH |
| Molecular Weight | 250.724 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.OC(CNC1=CC=CC=N1)C2=CC=CC=C2
InChI
InChIKey=HYYDHUILGLWOOP-UHFFFAOYSA-N
InChI=1S/C13H14N2O.ClH/c16-12(11-6-2-1-3-7-11)10-15-13-8-4-5-9-14-13;/h1-9,12,16H,10H2,(H,14,15);1H
Approval Year
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
Sources: https://www.ncbi.nlm.nih.gov/pubmed/13999595 |
Primary | Analexin Approved UseAnalgesic, Muscle relaxant Launch Date1959 |
Doses
| Dose | Population | Adverse events |
|---|---|---|
400 mg 2 times / day multiple, oral Dose: 400 mg, 2 times / day Route: oral Route: multiple Dose: 400 mg, 2 times / day Sources: |
unhealthy, 70 years |
Disc. AE: Liver injury... AEs leading to discontinuation/dose reduction: Liver injury Sources: |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Liver injury | Disc. AE | 400 mg 2 times / day multiple, oral Dose: 400 mg, 2 times / day Route: oral Route: multiple Dose: 400 mg, 2 times / day Sources: |
unhealthy, 70 years |
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C29696
Created by
admin on Mon Mar 31 18:04:16 GMT 2025 , Edited by admin on Mon Mar 31 18:04:16 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
17777
Created by
admin on Mon Mar 31 18:04:16 GMT 2025 , Edited by admin on Mon Mar 31 18:04:16 GMT 2025
|
PRIMARY | |||
|
100000086987
Created by
admin on Mon Mar 31 18:04:16 GMT 2025 , Edited by admin on Mon Mar 31 18:04:16 GMT 2025
|
PRIMARY | |||
|
C84055
Created by
admin on Mon Mar 31 18:04:16 GMT 2025 , Edited by admin on Mon Mar 31 18:04:16 GMT 2025
|
PRIMARY | |||
|
206-308-3
Created by
admin on Mon Mar 31 18:04:16 GMT 2025 , Edited by admin on Mon Mar 31 18:04:16 GMT 2025
|
PRIMARY | |||
|
9469
Created by
admin on Mon Mar 31 18:04:16 GMT 2025 , Edited by admin on Mon Mar 31 18:04:16 GMT 2025
|
PRIMARY | |||
|
M574V6XQH7
Created by
admin on Mon Mar 31 18:04:16 GMT 2025 , Edited by admin on Mon Mar 31 18:04:16 GMT 2025
|
PRIMARY | |||
|
326-43-2
Created by
admin on Mon Mar 31 18:04:16 GMT 2025 , Edited by admin on Mon Mar 31 18:04:16 GMT 2025
|
PRIMARY | |||
|
CHEMBL1697767
Created by
admin on Mon Mar 31 18:04:16 GMT 2025 , Edited by admin on Mon Mar 31 18:04:16 GMT 2025
|
PRIMARY | |||
|
m8702
Created by
admin on Mon Mar 31 18:04:16 GMT 2025 , Edited by admin on Mon Mar 31 18:04:16 GMT 2025
|
PRIMARY | Merck Index | ||
|
SUB02134MIG
Created by
admin on Mon Mar 31 18:04:16 GMT 2025 , Edited by admin on Mon Mar 31 18:04:16 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD